SREBF1 and fatty liver disease: Inhibition of the AMPK pathway promotes the transcription and translation of lipogenic genes, including fatty acid synthase (FASN) and encoding sterol regulatory element-binding protein 1 (SREBP1) within hepatocytes, finally promoting hepatic steatosis.